Annuncio • May 28
LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 18, 2026 LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 18, 2026, at 15:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan China Price Target Changed • Apr 30
Price target decreased by 8.4% to CN¥18.00 Down from CN¥19.64, the current price target is an average from 10 analysts. New target price is 29% above last closing price of CN¥14.00. Stock is down 31% over the past year. The company is forecast to post earnings per share of CN¥0.89 for next year compared to CN¥0.50 last year. Major Estimate Revision • Apr 29
Consensus EPS estimates fall by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥24.5b to CN¥23.9b. EPS estimate also fell from CN¥1.06 per share to CN¥0.931 per share. Net income forecast to grow 88% next year vs 18% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥19.64 to CN¥18.70. Share price rose 2.8% to CN¥14.11 over the past week. Reported Earnings • Apr 23
First quarter 2026 earnings: EPS exceeds analyst expectations First quarter 2026 results: EPS: CN¥0.35 (up from CN¥0.33 in 1Q 2025). Revenue: CN¥5.48b (flat on 1Q 2025). Net income: CN¥263.9m (up 5.3% from 1Q 2025). Profit margin: 4.8% (up from 4.6% in 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 58%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Annuncio • Mar 30
LBX Pharmacy Chain Joint Stock Company to Report Q1, 2026 Results on Apr 23, 2026 LBX Pharmacy Chain Joint Stock Company announced that they will report Q1, 2026 results on Apr 23, 2026 Buy Or Sell Opportunity • Feb 02
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to CN¥15.06. The fair value is estimated to be CN¥19.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.9% over the last 3 years. Earnings per share has declined by 20%. For the next 3 years, revenue is forecast to grow by 8.2% per annum. Earnings are also forecast to grow by 25% per annum over the same time period. Annuncio • Dec 26
LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2025 Results on Apr 23, 2026 LBX Pharmacy Chain Joint Stock Company announced that they will report fiscal year 2025 results on Apr 23, 2026 Reported Earnings • Oct 29
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: EPS: CN¥0.18 (up from CN¥0.17 in 3Q 2024). Revenue: CN¥5.30b (flat on 3Q 2024). Net income: CN¥130.8m (up 2.6% from 3Q 2024). Profit margin: 2.5% (up from 2.4% in 3Q 2024). Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) also missed analyst estimates by 9.1%. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 17% per year. Annuncio • Sep 30
LBX Pharmacy Chain Joint Stock Company to Report Q3, 2025 Results on Oct 29, 2025 LBX Pharmacy Chain Joint Stock Company announced that they will report Q3, 2025 results on Oct 29, 2025 Major Estimate Revision • Aug 27
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥23.6b to CN¥22.5b. EPS estimate also fell from CN¥1.08 per share to CN¥0.961 per share. Net income forecast to grow 73% next year vs 60% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥23.04 to CN¥22.26. Share price fell 2.9% to CN¥18.18 over the past week. Major Estimate Revision • Jul 11
Consensus revenue estimates decrease by 11%, EPS upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥23.6b to CN¥21.0b. EPS estimate increased from CN¥1.05 to CN¥1.08 per share. Net income forecast to grow 68% next year vs 68% growth forecast for Consumer Retailing industry in China. Consensus price target broadly unchanged at CN¥23.77. Share price fell 3.7% to CN¥19.34 over the past week. New Risk • Jul 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.8% average weekly change). Profit margins are more than 30% lower than last year (2.0% net profit margin). Annuncio • Jun 30
LBX Pharmacy Chain Joint Stock Company to Report First Half, 2025 Results on Aug 30, 2025 LBX Pharmacy Chain Joint Stock Company announced that they will report first half, 2025 results on Aug 30, 2025 Annuncio • Jun 09
LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 30, 2025 LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 30, 2025, at 15:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan China Reported Earnings • May 01
Full year 2024 earnings released: EPS: CN¥0.68 (vs CN¥1.22 in FY 2023) Full year 2024 results: EPS: CN¥0.68 (down from CN¥1.22 in FY 2023). Revenue: CN¥22.4b (flat on FY 2023). Net income: CN¥519.1m (down 44% from FY 2023). Profit margin: 2.3% (down from 4.1% in FY 2023). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat. Annuncio • Mar 28
LBX Pharmacy Chain Joint Stock Company to Report Q1, 2025 Results on Apr 30, 2025 LBX Pharmacy Chain Joint Stock Company announced that they will report Q1, 2025 results on Apr 30, 2025 Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to CN¥19.24, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 13x in the Consumer Retailing industry in China. Total loss to shareholders of 4.4% over the past three years. Annuncio • Dec 27
LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2024 Results on Apr 30, 2025 LBX Pharmacy Chain Joint Stock Company announced that they will report fiscal year 2024 results on Apr 30, 2025 Major Estimate Revision • Dec 10
Consensus EPS estimates increase by 13% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from CN¥1.17 to CN¥1.31. Revenue forecast steady at CN¥22.8b. Net income forecast to grow 23% next year vs 44% growth forecast for Consumer Retailing industry in China. Consensus price target up from CN¥25.50 to CN¥26.24. Share price was steady at CN¥18.98 over the past week. Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥19.25, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Consumer Retailing industry in China. Total loss to shareholders of 23% over the past three years. Reported Earnings • Oct 30
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: CN¥0.17 (down from CN¥0.26 in 3Q 2023). Revenue: CN¥5.29b (up 1.2% from 3Q 2023). Net income: CN¥127.4m (down 37% from 3Q 2023). Profit margin: 2.4% (down from 3.9% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) also missed analyst estimates by 36%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Upcoming Dividend • Oct 03
Upcoming dividend of CN¥0.33 per share Eligible shareholders must have bought the stock before 10 October 2024. Payment date: 10 October 2024. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 2.9%. Within top quartile of Chinese dividend payers (2.2%). Higher than average of industry peers (1.9%). Annuncio • Sep 30
LBX Pharmacy Chain Joint Stock Company to Report Q3, 2024 Results on Oct 30, 2024 LBX Pharmacy Chain Joint Stock Company announced that they will report Q3, 2024 results on Oct 30, 2024 Price Target Changed • Sep 20
Price target decreased by 12% to CN¥26.64 Down from CN¥30.14, the current price target is an average from 11 analysts. New target price is 88% above last closing price of CN¥14.18. Stock is down 29% over the past year. The company is forecast to post earnings per share of CN¥1.43 for next year compared to CN¥1.22 last year. Valuation Update With 7 Day Price Move • Sep 18
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥13.28, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 10x in the Consumer Retailing industry in China. Total loss to shareholders of 48% over the past three years. Major Estimate Revision • Sep 07
Consensus EPS estimates fall by 29% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥26.0b to CN¥23.6b. EPS estimate also fell from CN¥2.08 per share to CN¥1.49 per share. Net income forecast to grow 6.3% next year vs 56% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥31.93 to CN¥30.14. Share price rose 33% to CN¥17.92 over the past week. New Risk • Sep 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Valuation Update With 7 Day Price Move • Sep 04
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥14.81, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 11x in the Consumer Retailing industry in China. Total loss to shareholders of 46% over the past three years. Buy Or Sell Opportunity • Sep 02
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 53% to CN¥12.24. The fair value is estimated to be CN¥15.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 9.8%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 46% in the next 2 years. Valuation Update With 7 Day Price Move • Jun 28
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥18.36, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 17x in the Consumer Retailing industry in China. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.59 per share. Annuncio • Jun 28
LBX Pharmacy Chain Joint Stock Company to Report First Half, 2024 Results on Aug 30, 2024 LBX Pharmacy Chain Joint Stock Company announced that they will report first half, 2024 results on Aug 30, 2024 Declared Dividend • Jun 23
Dividend increased to CN¥0.66 Dividend of CN¥0.66 is 32% higher than last year. Ex-date: 27th June 2024 Payment date: 27th June 2024 Dividend yield will be 2.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (40% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 19% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 65% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annuncio • May 24
LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024 LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024, at 14:30 China Standard Time. Location: 15F, No. 808, Qingzhuhu Road, Kaifu District, Changsha, Hunan China Reported Earnings • Apr 30
Full year 2023 earnings: EPS in line with expectations, revenues disappoint Full year 2023 results: EPS: CN¥1.59 (up from CN¥1.36 in FY 2022). Revenue: CN¥22.4b (up 11% from FY 2022). Net income: CN¥929.0m (up 18% from FY 2022). Profit margin: 4.1% (up from 3.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Annuncio • Mar 29
LBX Pharmacy Chain Joint Stock Company to Report Q1, 2024 Results on Apr 30, 2024 LBX Pharmacy Chain Joint Stock Company announced that they will report Q1, 2024 results on Apr 30, 2024 Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥31.93, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 18x in the Consumer Retailing industry in China. Total loss to shareholders of 45% over the past three years. Annuncio • Dec 29
LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2023 Results on Apr 30, 2024 LBX Pharmacy Chain Joint Stock Company announced that they will report fiscal year 2023 results on Apr 30, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2023 results: EPS: CN¥0.34 (up from CN¥0.26 in 3Q 2022). Revenue: CN¥5.23b (up 9.3% from 3Q 2022). Net income: CN¥203.3m (up 33% from 3Q 2022). Profit margin: 3.9% (up from 3.2% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.4%. Earnings per share (EPS) exceeded analyst estimates by 3.6%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 05
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: EPS: CN¥0.38. Revenue: CN¥5.37b (up 11% from 2Q 2022). Net income: CN¥221.9m (up 3.4% from 2Q 2022). Profit margin: 4.1% (down from 4.4% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Reported Earnings • Apr 29
Full year 2022 earnings released: EPS: CN¥1.36 (vs CN¥1.26 in FY 2021) Full year 2022 results: EPS: CN¥1.36 (up from CN¥1.26 in FY 2021). Revenue: CN¥20.2b (up 28% from FY 2021). Net income: CN¥785.0m (up 17% from FY 2021). Profit margin: 3.9% (down from 4.3% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Buying Opportunity • Apr 19
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 16%. The fair value is estimated to be CN¥43.87, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 18% per annum over the same time period. Price Target Changed • Apr 03
Price target increased by 8.1% to CN¥45.36 Up from CN¥41.97, the current price target is an average from 6 analysts. New target price is 31% above last closing price of CN¥34.65. Stock is up 24% over the past year. The company is forecast to post earnings per share of CN¥1.40 for next year compared to CN¥1.26 last year. Buying Opportunity • Apr 03
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 19%. The fair value is estimated to be CN¥43.87, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. Revenue is forecast to grow by 44% in 2 years. Earnings is forecast to grow by 52% in the next 2 years. Price Target Changed • Feb 03
Price target increased by 7.5% to CN¥43.11 Up from CN¥40.10, the current price target is an average from 7 analysts. New target price is 12% above last closing price of CN¥38.45. Stock is up 18% over the past year. The company is forecast to post earnings per share of CN¥1.40 for next year compared to CN¥1.26 last year. Price Target Changed • Jan 14
Price target increased to CN¥41.97 Up from CN¥39.10, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of CN¥42.00. Stock is up 12% over the past year. The company is forecast to post earnings per share of CN¥1.39 for next year compared to CN¥1.26 last year. Buying Opportunity • Dec 22
Now 22% undervalued Over the last 90 days, the stock is up 27%. The fair value is estimated to be CN¥48.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. Revenue is forecast to grow by 43% in 2 years. Earnings is forecast to grow by 51% in the next 2 years. Buying Opportunity • Dec 06
Now 21% undervalued Over the last 90 days, the stock is up 28%. The fair value is estimated to be CN¥52.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. Revenue is forecast to grow by 42% in 2 years. Earnings is forecast to grow by 51% in the next 2 years. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Lianfeng Wu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 30
Third quarter 2022 earnings: EPS misses analyst expectations Third quarter 2022 results: EPS: CN¥0.26 (up from CN¥0.24 in 3Q 2021). Revenue: CN¥4.79b (up 25% from 3Q 2021). Net income: CN¥153.1m (up 21% from 3Q 2021). Profit margin: 3.2% (down from 3.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 25%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jun 29
Investor sentiment deteriorated over the past week After last week's 24% share price decline to CN¥33.36, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total loss to shareholders of 21% over the past three years. Price Target Changed • May 21
Price target decreased to CN¥58.58 Down from CN¥63.49, the current price target is an average from 11 analysts. New target price is 61% above last closing price of CN¥36.32. Stock is down 32% over the past year. The company is forecast to post earnings per share of CN¥1.86 for next year compared to CN¥1.64 last year. Major Estimate Revision • May 05
Consensus EPS estimates fall by 21% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥19.5b to CN¥18.5b. EPS estimate also fell from CN¥2.04 per share to CN¥1.61 per share. Net income forecast to grow 21% next year vs 30% growth forecast for Consumer Retailing industry in China. Consensus price target down from CN¥63.49 to CN¥59.92. Share price rose 10.0% to CN¥32.24 over the past week. Reported Earnings • Apr 30
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2022 results: EPS: CN¥0.53. Revenue: CN¥4.14b (up 14% from 1Q 2021). Net income: CN¥241.8m (up 6.3% from 1Q 2021). Profit margin: 5.8% (down from 6.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 8.1%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 22%, compared to a 16% growth forecast for the industry in China. Price Target Changed • Apr 27
Price target decreased to CN¥63.49 Down from CN¥81.75, the current price target is an average from 8 analysts. New target price is 112% above last closing price of CN¥29.90. Stock is down 47% over the past year. The company is forecast to post earnings per share of CN¥1.70 for next year compared to CN¥1.54 last year. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Yang Haiyu was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.34 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥3.82b (up 11% from 3Q 2020). Net income: CN¥126.8m (down 16% from 3Q 2020). Profit margin: 3.3% (down from 4.4% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Annuncio • Aug 26
LBX Pharmacy Chain Joint Stock Company (SHSE:603883) agreed to acquire 51% stake in Hebei Hua Tuo Pharmacy Medicine Chain Co., Ltd. from Zhang Weijun, Tian Jinping, Ma Zhirong and Guo Zhihong fro CNY 1.4 billion. LBX Pharmacy Chain Joint Stock Company (SHSE:603883) agreed to acquire 51% stake in Hebei Hua Tuo Pharmacy Medicine Chain Co., Ltd. from Zhang Weijun, Tian Jinping, Ma Zhirong and Guo Zhihong fro CNY 1.4 billion on August 24, 2021. Under the terms of consideration, The first advance payment: within 7 working days after this agreement is signed and effective, 20% of the total transfer price shall be paid, totaling CNY 285.6 million and The second transfer price: After the completion of the target company’s assets divestiture, the target equity change, the establishment of the target company’s board of directors, and the completion of the above work within seven working days, 40% of the total transfer price shall be paid, totaling CNY 571.2 million and The third transfer payment: 10% of the total transfer price shall be paid within 7 working days after the establishment of the board of directors, totaling CNY 142.8 million and The fourth transfer price: within 7 working days after the seller provides the personal income tax payment voucher, 10% of the total transfer price shall be paid, totaling CNY 142.8 million and The fifth transfer price: After auditing, evaluating and confirming that the net assets of the target company meet stipulated in this agreement on the delivery date, within 7 working days 10% of the total transfer price shall be paid, totaling RMB 142.8 million and The sixth transfer price: the amount of CNY 142.8 million yuan is the deposit, and the guarantee period is one year (calculated from the delivery date). After the expiration, the two parties confirm that the seller has no deductions for payment and shall pay within 7 working days. The consideration will be funded through its own funds. Hebei Hua Tuo Pharmacy Medicine Chain reported total assets of CNY 821.6 million and total common equity of CNY 227.7 million till April 31, 2021. LBX Pharmacy Chain Joint Stock Company's board approved the deal. Price Target Changed • Aug 20
Price target decreased to CN¥75.25 Down from CN¥81.75, the current price target is an average from 7 analysts. New target price is 53% above last closing price of CN¥49.27. Stock is down 36% over the past year. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.35 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥3.82b (up 12% from 2Q 2020). Net income: CN¥178.3m (up 28% from 2Q 2020). Profit margin: 4.7% (up from 4.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Price Target Changed • Aug 14
Price target decreased to CN¥79.67 Down from CN¥86.50, the current price target is an average from 6 analysts. New target price is 65% above last closing price of CN¥48.28. Stock is down 31% over the past year. Price Target Changed • Jun 16
Price target decreased to CN¥86.50 Down from CN¥93.56, the current price target is an average from 7 analysts. New target price is 61% above last closing price of CN¥53.65. Stock is down 20% over the past year. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.49 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥3.64b (up 11% from 1Q 2020). Net income: CN¥227.5m (up 16% from 1Q 2020). Profit margin: 6.3% (up from 6.0% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Is New 90 Day High Low • Mar 09
New 90-day low: CN¥61.85 The company is down 10.0% from its price of CN¥68.36 on 09 December 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥48.82 per share. Annuncio • Feb 09
Laobaixing Pharmacy Chain Joint Stock Company (SHSE:603883) completed the acquisition of Jinan Xincheng Enterprise Management Co., Ltd. from Shanghai Chengzhen Enterprise Management Partnership (Limited Partnership), Shanghai Boyi Enterprise Management Consulting Service Center (Limited Partnership) and Shanghai Xinzhen Marketing Planning Service Center (Limited Partnership). Laobaixing Pharmacy Chain Joint Stock Company (SHSE:603883) entered into an agreement to acquire Jinan Xincheng Enterprise Management Co., Ltd. from Shanghai Chengzhen Enterprise Management Partnership (Limited Partnership), Shanghai Boyi Enterprise Management Consulting Service Center (Limited Partnership) and Shanghai Xinzhen Marketing Planning Service Center (Limited Partnership) for CNY 680 million on December 18, 2020. As part of the transaction, Laobaixing Pharmacy Chain will pay CNY 20.4 million, CNY 20.6 million and CNY 27 million to Shanghai Chengzhen Enterprise Management Partnership, Shanghai Boyi Enterprise Management Consulting Service and Shanghai Xinzhen Marketing Planning Service Center, respectively. Laobaixing Pharmacy Chain will pay CNY 136 million within 7 working days after the signing of this agreement, CNY 476 million within seven working days after the completion of the settlement and the balance of CNY 68 million within seven working days of the settlement of related party's corresponding borrowings. The Board of Directors of Laobaixing Pharmacy Chain approved the transaction and no need to submit it to the general meeting of shareholders for review.
Laobaixing Pharmacy Chain Joint Stock Company (SHSE:603883) completed the acquisition of Jinan Xincheng Enterprise Management Co., Ltd. from Shanghai Chengzhen Enterprise Management Partnership (Limited Partnership), Shanghai Boyi Enterprise Management Consulting Service Center (Limited Partnership) and Shanghai Xinzhen Marketing Planning Service Center (Limited Partnership) on February 8, 2020. Laobaixing Pharmacy Chain used own funds of CNY 680 million to acquire Jinan Xincheng Enterprise Management. Is New 90 Day High Low • Jan 13
New 90-day high: CN¥81.64 The company is up 1.0% from its price of CN¥80.70 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.07 per share. Valuation Update With 7 Day Price Move • Jan 12
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥78.46, the stock is trading at a trailing P/E ratio of 53.3x, up from the previous P/E ratio of 45.3x. This compares to an average P/E of 32x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 84%. Is New 90 Day High Low • Dec 28
New 90-day low: CN¥63.60 The company is down 22% from its price of CN¥81.13 on 29 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.07 per share. Is New 90 Day High Low • Dec 12
New 90-day low: CN¥65.89 The company is down 19% from its price of CN¥81.54 on 11 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.07 per share. Is New 90 Day High Low • Nov 18
New 90-day low: CN¥67.21 The company is down 8.0% from its price of CN¥73.07 on 20 August 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥53.67 per share. Price Target Changed • Nov 18
Price target raised to CN¥97.98 Up from CN¥89.75, the current price target is an average from 8 analysts. The new target price is 46% above the current share price of CN¥67.21. As of last close, the stock is up 33% over the past year. Annuncio • Nov 05
Laobaixing Reportedly in Merger Talks with Yixintang Laobaixing Pharmacy Chain Joint Stock Company (SHSE:603883) and Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) are in advanced talks to create China’s biggest drugstore chain via a share swap, three people familiar with the matter said. Laobaixing’s founders, Xie Zilong and Chen Xiulan, are expected to have a bigger stake in the merged firm than Yixintang’s founder Ruan Hongxian, said two of the people. The talks have been ongoing for more than three months, the two people said. One person said the firms are aiming to finalize and announce the deal in the coming days, adding that Laobaixing would remain the listed entity. The sources declined to be identified as the discussions were not public. Laobaixing, Yixintang did not immediately respond to requests for comment yesterday. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥601.8m, up 19% from the prior year. Total revenue was CN¥13.4b over the last 12 months, up 21% from the prior year. Annuncio • Oct 30
Laobaixing Pharmacy Chain Joint Stock Company to Report Q3, 2020 Results on Oct 30, 2020 Laobaixing Pharmacy Chain Joint Stock Company announced that they will report Q3, 2020 results on Oct 30, 2020 Annuncio • Jul 09
Laobaixing Pharmacy Chain Joint Stock Company to Report First Half, 2020 Results on Aug 21, 2020 Laobaixing Pharmacy Chain Joint Stock Company announced that they will report first half, 2020 results on Aug 21, 2020 
